| pubmed-article:20514290 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0599779 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0014132 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0033375 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0796392 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:20514290 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:20514290 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20514290 | pubmed:dateCreated | 2010-6-1 | lld:pubmed |
| pubmed-article:20514290 | pubmed:abstractText | Estrogen-induced pituitary prolactin-producing tumors (PRLoma) in F344 rats express a high level of vascular endothelial growth factor (VEGF) associated with marked angiogenesis and angiectasis. To investigate whether tumor development in E2-induced PRLoma is inhibited by anti-VEGF monoclonal antibody (G6-31), we evaluated tumor growth and observed the vascular structures. With simultaneous treatment with G6-31 for the latter three weeks of the 13-week period of E2 stimulation (E2+G6-31 group), the following inhibitory effects on the PRLoma were observed in the E2+G6-31 group as compared with the E2-only group. In the E2+G6-31 group, a tendency to reduction in pituitary weight was observed and significant differences were observed as (1) reductions in the Ki-67-positive anterior cells, (2) increases in TUNEL-positive anterior cells, and (3) repair of the microvessel count by CD34-immunohistochemistry. The characteristic "blood lakes" in PRLomas were improved and replaced by repaired microvascular structures on 3D observation using confocal laser scanning microscope. These inhibitory effects due to anti-VEGF antibody might be related to the autocrine/paracrine action of VEGF on the tumor cells, because VEGF and its receptor are co-expressed on the tumor cells. Thus, our results demonstrate that anti-VEGF antibody exerted inhibitory effects on pituitary tumorigenesis in well-established E2 induced PRLomas. | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20514290 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20514290 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:20514290 | pubmed:month | May | lld:pubmed |
| pubmed-article:20514290 | pubmed:issn | 1347-5800 | lld:pubmed |
| pubmed-article:20514290 | pubmed:author | pubmed-author:ItohJohbuJ | lld:pubmed |
| pubmed-article:20514290 | pubmed:author | pubmed-author:TakekoshiSusu... | lld:pubmed |
| pubmed-article:20514290 | pubmed:author | pubmed-author:MiyajimaKatsu... | lld:pubmed |
| pubmed-article:20514290 | pubmed:author | pubmed-author:OsamuraRobert... | lld:pubmed |
| pubmed-article:20514290 | pubmed:author | pubmed-author:MiyakoshiTaka... | lld:pubmed |
| pubmed-article:20514290 | pubmed:author | pubmed-author:KakimotoKochi... | lld:pubmed |
| pubmed-article:20514290 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20514290 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20514290 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:20514290 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20514290 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20514290 | pubmed:pagination | 33-44 | lld:pubmed |
| pubmed-article:20514290 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20514290 | pubmed:articleTitle | Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors. | lld:pubmed |
| pubmed-article:20514290 | pubmed:affiliation | Department of Pathology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. | lld:pubmed |
| pubmed-article:20514290 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20514290 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20514290 | lld:pubmed |
